Cell Press: working to publish science that inspires.

Cell Press is proud to publish the Molecular Therapy family of journals. We publish over 50 scientific journals across the life, physical, earth, and health sciences. Our story began over 45 years ago with the journal Cell and a commitment to publishing exciting biology. Today, we are bringing our editorial excellence, commitment to innovation, unparalleled reach and visibility, and passion for advocacy to all areas of scientific exploration as we work to publish and share science that inspires.

Brands: Cell Press is proud to publish Molecular Therapy, Molecular Therapy – Methods & Clinical Development, Molecular Therapy – Nucleic Acids, and Molecular Therapy - Oncolytics, official journals of ASGCT


 Products

  • Cell Press
    The Molecular Therapy family of journals, published on behalf of ASGCT, support the Society’s mission to advance knowledge, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease....

  • Molecular Therapy is a leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials.

    Molecular Therapy—Methods & Clinical Development is an open-access journal publishing peer-reviewed methods and procedures as well as translational advances in the broad array of fields under the Molecular Therapy umbrella. Focus areas are advances in cell and gene therapy and how they are translated and applied in the clinical setting.

    Molecular Therapy — Nucleic Acids is an open-access journal publishing basic, translational, and clinical research in the broad fields of nucleic-acid-based therapeutics to treat and/or correct genetic and acquired disease.

    Molecular Therapy—Oncolytics is an open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. The journal provides a unique forum for work in the burgeoning fields of oncolytic virotherapy, as well as T cell- and stem cell-based therapies.